| Name | Title | Contact Details |
|---|
Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.
Chicago Advertising & Design is a Chicago, IL-based company in the Business Services sector.
News-Press & Gazette Company & NPG Newspapers Inc is a Saint Joseph, MO-based company in the Business Services sector.
The United States Senate is the upper chamber of the United States Congress, which along with the United States House of Representatives—the lower chamber—comprises the legislature of the United States.
Vorlon enables continuous near real-time detection and identification of third-party apps consuming your data. Our agentless patent-pending solution facilitates risk profiling of apps, and provides AI-driven behavioral analytics with response recommendations. Visit our website at vorlonsecurity.com to learn more.